Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Operating Leases (2020 - 2025)

Korro Bio (KRRO) has disclosed Operating Leases for 6 consecutive years, with $41.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 0.63% year-over-year to $41.5 million, compared with a TTM value of $41.5 million through Sep 2025, down 0.63%, and an annual FY2024 reading of $43.5 million, up 39.29% over the prior year.
  • Operating Leases was $41.5 million for Q3 2025 at Korro Bio, down from $42.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $45.2 million in Q1 2025 and bottomed at $209000.0 in Q4 2022.
  • Average Operating Leases over 5 years is $31.8 million, with a median of $30.0 million recorded in 2021.
  • The sharpest move saw Operating Leases plummeted 99.28% in 2022, then skyrocketed 14835.89% in 2023.
  • Year by year, Operating Leases stood at $28.9 million in 2021, then tumbled by 99.28% to $209000.0 in 2022, then surged by 14835.89% to $31.2 million in 2023, then skyrocketed by 39.29% to $43.5 million in 2024, then decreased by 4.5% to $41.5 million in 2025.
  • Business Quant data shows Operating Leases for KRRO at $41.5 million in Q3 2025, $42.2 million in Q2 2025, and $45.2 million in Q1 2025.